News Releases

September 2021

September 23, 2021 9/23/2021 Takeda Breaks Ground on its First Zero Energy Building in Singapore

September 22, 2021 9/22/2021 Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries

September 16, 2021 9/16/2021 Takeda Continues to Advance Growth Strategy with Sale Of Non-Core Assets in Latin America

September 15, 2021 9/15/2021 Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

September 7, 2021 9/7/2021 Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan

September 1, 2021 9/1/2021 Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

August 2021

August 6, 2021 8/6/2021 Takeda Updates its Q1 FY2021 Earnings Materials to Reflect Impact of Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

August 5, 2021 8/5/2021 Final Results from the Longest Hereditary Angioedema Study

August 1, 2021 8/1/2021 Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie